Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis

To the editor: Acute myeloid leukemia (AML) is the most common acute leukemia in adults with an annual, age-adjusted incidence of 3.5/100 000 men and women rising to 15 to 20 above the age of 60 years.[1][1] Extensive work has now led to the elucidation of its genomic backbone, a refined